FDA Ready To Change Bioequivalence Standards, Pending Advisory Committee Input
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency appears ready to narrow bioequivalence standards across the board for generic drug approvals and set up specific requirements for certain drugs with complicated dosing, but is looking to the Pharmaceutical Science advisory panel for final advice on whether the moves are necessary.
You may also be interested in...
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies
FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.
Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues
Citizen petition tells FDA not to worry about bioequivalence tests in fasting patients, but focus on the product's three-stage release characteristics.